Citi: Adds WUXI BIO (02269) to 90-day upside catalyst watch list; expects full-year guidance may be raised in Q4
Citi believes that WUXI BIO may raise its overall guidance in Q4, and the biosimilar development agreement reached with Fresenius may also prompt the company to raise its long-term target for CMO revenue.
Citi issued a research report stating that it has added WUXI BIO (02269) to its 90-day upside catalyst watch list. The bank believes the company may raise its overall guidance in Q4, and the biosimilar development agreement reached with Fresenius may also prompt the company to raise its long-term target for contract manufacturing organization (CMO) revenue. Citi said WUXI BIO is also one of its preferred AI-driven drug discovery (AIDD) beneficiary stocks, and believes the company's AIDD capabilities are being undervalued by the market.
Related Articles
FMR LLC reduces its holdings in SUN HING VISION (00125) by 56,000 shares at approximately HK$0.28 per share.
Advanced Micro-Fabrication Equipment Inc. China (688012.SH) plans to repurchase company shares for RMB400 million to RMB500 million.
AIRDOC-B (02251) repurchased 16,300 shares on November 5 for approximately HK$148,200.
FMR LLC reduces its holdings in SUN HING VISION (00125) by 56,000 shares at approximately HK$0.28 per share.
Advanced Micro-Fabrication Equipment Inc. China (688012.SH) plans to repurchase company shares for RMB400 million to RMB500 million.
AIRDOC-B (02251) repurchased 16,300 shares on November 5 for approximately HK$148,200.
